Collectively, the studies presented herein provide evidence that pooled peptides from HER-2/neu-overexpressing ovarian tumours can be utilised in cellular adoptive immunotherapy of patients with HER-2/neu+ ovarian cancer. Here, ERBB2 is linked to ovarian neoplasm.